Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055Gayle Marshall, Sylvie M. Guichard, Dan Heathcote et al.|Biochemical Society Transactions|2011Cited by 38
Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancerSylvie M. Guichard, Martin Pass, Zoë Howard et al.|Cancer Research|2012Cited by 17